IMV Inc. is a clinical-stage immuno-oncology company advancing a portfolio of therapies based on the Company’s immune-educating platform, DPX™. Through a differentiated mechanism of action, the DPX ...

Operator: Good day and thank you for standing by. Welcome to IMV's Fourth Quarter and Fiscal Year 2022 Results Webcast. Please be advised that today's conference is being recorded. I would now like to ...

Good morning, everyone. I am Joy Besenger, Head of Investor Relations and Corporate strategies for IMV and I'm pleased to welcome you all to our First Quarter 2022 Clinical and Operational Update ...

Get instant alerts when news breaks on your stocks. Claim your 1-week free trial to StreetInsider Premium here. DARTMOUTH, Nova Scotia & CAMBRIDGE, Mass.--(BUSINESS WIRE)-- IMV Inc. (Nasdaq: IMV; TSX: ...

IMV produces an annual series of proprietary ServiceTrak™ Imaging reports derived from extensive phone interviews with imaging professionals in hospital departments and independent imaging centers in ...

IMV, Inc. (IMV) Q3 2022 Earnings Conference Call November 11, 2022 08:00 AM ET Company Participants Brittany Davison - Chief Accounting Officer Andrew Hall ...

IMV initiated a Phase 1 clinical trial evaluating both MVP-S and DPX-SurMAGE, in patients with non-muscle invasive bladder cancer (NMIBC) in early 2022. The first patient was dosed early April 2022.

ARLINGTON, Va., Nov. 28, 2022 /PRNewswire/ -- Today IMV, part of Science and Medicine Group, the leading market research and business intelligence provider to the laboratory diagnostic industry, ...

News and research before you hear about it on CNBC and others. Claim your 1-week free trial to StreetInsider Premium here. Positive clinical results in bladder cancer were presented at the AACR annual ...